Improved Biodistribution and Extended Serum Half-Life of a Bacteriophage Endolysin by Albumin Binding Domain Fusion
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improved Biodistribution and Extended Serum Half-Life of a Bacteriophage Endolysin by Albumin Binding Domain Fusion
Authors
Keywords
-
Journal
Frontiers in Microbiology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-11-27
DOI
10.3389/fmicb.2018.02927
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period
- (2016) Soo Youn Jun et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- IBS: an illustrator for the presentation and visualization of biological sequences: Fig. 1.
- (2015) Wenzhong Liu et al. BIOINFORMATICS
- Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection
- (2015) Mathias Schmelcher et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein
- (2014) Johan Seijsing et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
- (2013) Vibha Jawa et al. CLINICAL IMMUNOLOGY
- Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein
- (2013) A. Orlova et al. JOURNAL OF NUCLEAR MEDICINE
- Bacteriophage endolysins as novel antimicrobials
- (2012) Mathias Schmelcher et al. Future Microbiology
- Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1
- (2012) Soo Youn Jun et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance
- (2011) Gregory Resch et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- PEGylating a bacteriophage endolysin inhibits its bactericidal activity
- (2011) Gregory Resch et al. AMB Express
- Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
- (2010) Katrin Knop et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Bacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens
- (2010) Vincent A. Fischetti INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
- LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells
- (2009) Stephen C. Becker et al. FEMS MICROBIOLOGY LETTERS
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
- (2008) Jessica E. Matthews et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Podocytes use FcRn to clear IgG from the glomerular basement membrane
- (2008) S. Akilesh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineering of a femtomolar affinity binding protein to human serum albumin
- (2008) A. Jonsson et al. PROTEIN ENGINEERING DESIGN & SELECTION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started